Integer to Showcase Innovations in Neuromodulation, Miniaturized Active Implantable Device Technology During NANS 2026 Annual Meeting
Rhea-AI Summary
Integer (NYSE: ITGR) will exhibit at the North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 22–25, 2026. Visit booth #115 to see Integer’s work on neuromodulation and miniaturized active implantable medical devices (AIMDs) aimed at accelerating development timelines and reducing risk for device makers.
Integer will highlight full-system capabilities—from high-performance batteries to integrated implantable pulse generators and lead systems—and showcase the Xcellion® Gen 3 Fast Charge Lithium Ion battery, which offers best-in-class runtime and recharges in as little as 30 minutes.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ITGR gained 2.37%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: LIVN -2.17%, BRKR -3.82%, HAE -3.88%, GKOS -0.42%, while TMDX +5.24%, pointing to stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 18 | Investor conferences | Positive | +1.0% | Management highlighted upcoming participation in two healthcare investor conferences. |
| Nov 04 | Share repurchase | Positive | +2.5% | Board authorized a <b>$200M</b> share repurchase program funded by cash and free cash flow. |
| Oct 24 | CEO transition | Neutral | -1.3% | Planned transition as Payman Khales assumed President and CEO role from retiring CEO. |
| Oct 23 | Q3 2025 earnings | Positive | -32.3% | Reported Q3 sales <b>$467.7M</b>, EPS <b>$1.79</b>, higher leverage at <b>$1.194B</b> debt and 3.0x ratio. |
| Sep 25 | Earnings call setup | Neutral | -1.2% | Scheduled Q3 2025 earnings call with webcast and replay details for investors. |
News-driven moves have generally aligned with tone, except the Q3 2025 earnings release, which saw a sharply negative reaction despite growth metrics and raised outlook.
Over the last several months, Integer announced Q3 2025 results with $467.7M in sales, higher adjusted operating income of $86M, and adjusted EPS of $1.79, but the stock fell 32.28%. The Board later authorized a $200M share repurchase program, which coincided with a 2.51% gain. Leadership transitioned as Payman Khales became President and CEO, followed by typical conference participation updates. Compared with these items, today’s NANS-focused technology showcase is more marketing- and positioning-oriented than financially driven.
Market Pulse Summary
This announcement highlights Integer’s neuromodulation and miniaturized implantable device capabilities ahead of the NANS 2026 meeting, including its Xcellion Gen 3 fast-charge battery that recharges in as little as 30 minutes. In the past six months, more material drivers included Q3 2025 results with $467.7M in sales and a $200M share repurchase authorization. Investors may watch how conference visibility translates into new development programs, as well as future earnings and leverage trends.
Key Terms
neuromodulation medical
active implantable medical devices medical
implantable pulse generator medical
lithium ion battery technical
AI-generated analysis. Not financial advice.
~ Attendees Invited to Visit Integer at Booth #115 ~
PLANO, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas from Jan. 22 – 25, 2026.
At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to accelerate development timelines and reduce risk for medical device companies bringing novel therapies to market.
“Miniaturization is transforming the future of implantable technologies, and we’re proud to partner with customers to make that future a reality,” said Jim Stephens, President, Cardiac Rhythm Management & Neuromodulation. “We invite attendees to visit booth #115 to see how Integer’s expertise – spanning every critical component from high-performance batteries to fully integrated implantable pulse generator and lead systems – can help enable our customers’ innovations.”
Attendees can also explore Integer’s Xcellion® Gen 3 Fast Charge Lithium Ion battery technology, which offers best-in-class runtime and recharges in as little as 30 minutes.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, Integer is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: | |||
| Kristen Stewart | Misty Tippen | |||
| kristen.stewart@integer.net | misty.tippen@integer.net | |||
| 551.337.3973 | 469.536.6702 |
FAQ
When and where will Integer (ITGR) exhibit at NANS 2026?
What technologies will Integer (ITGR) showcase at NANS 2026?
What is notable about Integer’s Xcellion Gen 3 battery featured by ITGR?
How can medical device companies engage with Integer (ITGR) at the show?
Will Integer (ITGR) demonstrate full implantable systems at NANS 2026?
Where can investors find more information about Integer (ITGR) after NANS 2026?
